Skip to main content
Back
Watch Compare

C4 Therapeutics, Inc.

Data quality: 100%
CCCC
Nasdaq Manufacturing Chemicals
$2.82
▼ $0.08 (-2.76%)
Mkt Cap: 275.16 M
Price
$2.82
Mkt Cap
275.16 M
Day Range
$2.67 — $3.01
52-Week Range
$1.09 — $3.82
Volume
18,114,639
Open $2.80
50D / 200D Avg
$2.44
15.81% above
50D / 200D Avg
$2.35
20.25% above

Quick Summary

Key Takeaways

Negative free cash flow of -99.30 M
Capital efficient — spends only 1.69% of revenue on capex

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)1.02%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-63.93%
Below sector avg (-53.47%)
ROIC-37.80%
Net Margin-292.08%
Op. Margin-320.53%

Safety

Debt / Equity
N/A
Current Ratio5.76
Interest CoverageN/A

Valuation

PE (TTM)
-2.62
Below sector avg (-1.47)
P/B Ratio1.78
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -2.6 -1.5
P/B 1.8 1.6
ROE % -63.9 -53.5
Net Margin % -292.1 -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

ETFs Holding This Stock

MSGGX MSGGX
0.23% weight
MISGX MISGX
0.23% weight
MSGAX MSGAX
0.23% weight
MSGRX MSGRX
0.23% weight
MSGCX MSGCX
0.23% weight
BRSIX BRSIX
0.20% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 1.02% Revenue Growth (3Y) 31.60%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 35.95 M Net Income (TTM) -104.99 M
ROE -63.93% ROA -37.36%
Gross Margin N/A Operating Margin -320.53%
Net Margin -292.08% Free Cash Flow (TTM) -99.30 M
ROIC -37.80% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 5.76
Interest Coverage N/A Asset Turnover 0.13
Working Capital 170.92 M Tangible Book Value 154.41 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2.62 Forward P/E N/A
P/B Ratio 1.78 P/S Ratio 7.65
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -36.09%
Market Cap 275.16 M Enterprise Value 216.35 M
Per Share
EPS (Diluted TTM) -1.27 Revenue / Share 0.37
FCF / Share -1.02 OCF / Share -1.01
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 1.69% FCF Conversion 94.58%
SBC-Adj. FCF -135.27 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 35.95 M 35.58 M 20.76 M 31.10 M —
Net Income -104.99 M -105.32 M -132.49 M -128.18 M -83.89 M
EPS (Diluted) -1.27 -1.52 -2.67 -2.62 —
Gross Profit — — — — —
Operating Income -115.22 M -119.61 M -139.03 M -129.53 M -82.13 M
EBITDA — — — — —
R&D Expenses 104.24 M 110.64 M 117.71 M 117.84 M 94.67 M
SG&A Expenses — — — — —
D&A 1.96 M 1.82 M 1.88 M 1.68 M 1.49 M
Interest Expense — — — — —
Income Tax 121,000.0 131,000.0 1.28 M 0.0 -626,000.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 359.08 M 349.60 M 376.45 M 430.84 M 506.77 M
Total Liabilities 102.49 M 133.62 M 130.34 M 141.61 M 117.16 M
Shareholders' Equity 256.59 M 215.99 M 246.11 M 289.23 M 389.61 M
Total Debt — — 11.48 M 11.48 M 10.77 M
Cash & Equivalents 74.60 M 55.50 M 126.59 M 29.75 M 76.12 M
Current Assets 258.11 M 257.77 M 271.19 M 287.56 M 325.69 M
Current Liabilities 33.03 M 45.18 M 42.77 M 44.55 M 51.25 M